Predictive Value of the Uric Acid/Albumin Ratio and Lactate in Sepsis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-15

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sepsis is a life-threatening condition characterized by organ dysfunction resulting from a dysregulated host response to infection and remains a leading cause of morbidity and mortality in intensive care units. Early identification of patients at high risk for adverse outcomes is essential for timely intervention and improved prognosis.

This prospective, single-center, non-interventional study aims to evaluate the predictive value of the combined use of the blood uric acid/albumin ratio (UAR) and serum lactate levels in patients aged 65 years and older who are admitted to the intensive care unit with a diagnosis of sepsis according to SEPSIS-3 criteria. Patients without acute kidney injury at admission and with at least 24 hours of intensive care follow-up will be included.

The primary outcome is the development of acute kidney injury within the first 7 days of ICU admission according to KDIGO criteria. Secondary outcomes include vasopressor requirement during ICU stay, changes in serum lactate levels over the first 24 hours, and 28-day mortality. The study seeks to determine whether the combination of UAR and lactate levels can serve as an easily accessible and clinically applicable biomarker to predict adverse outcomes and support prognostic assessment and treatment strategies in sepsis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evaluation of Candidate Biomarkers to Predict Disease Severity and Acute Kidney Injury in Sepsis Patients

NCT05310812

Sepsis Septic Shock Acute Kidney Injury

COMPLETED

Prediction of Acute Kidney Injury in Patients With Sepsis Using Venous Excess Ultrasound Score

NCT06176807

Intensive Care Unit

RECRUITING

Urinary Actin, as a Potential Marker of Sepsis-related Acute Kidney Injury

NCT04968262

Sepsis Acute Kidney Injury Due to Sepsis

COMPLETED

Optimization of Therapeutic Human Serum Albumin Infusion in Selected Critically Ill Patients

NCT02755155

Shock Systemic Inflammatory Response Syndrome (SIRS) Hypoalbuminaemia

TERMINATED PHASE4

Validation of SOFA-2 for Mortality and Sepsis-3 Prevalence in Turkey

NCT07300306

Sepsis Septic Shock Critical Illness +1 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis-Related Mortality Acute Kidney Injury

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non-interventional / Observational Study

This is a non-interventional, observational study. No diagnostic or therapeutic intervention will be applied beyond routine clinical care. Blood uric acid, albumin, and serum lactate levels measured as part of standard intensive care management will be recorded at admission, and lactate levels will be reassessed at 24 hours. Patients will be followed prospectively during their intensive care stay to evaluate the development of acute kidney injury, vasopressor requirement, and 28-day mortality.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 65 years and older
* Diagnosis of sepsis according to SEPSIS-3 criteria
* Admission to the intensive care unit
* No acute kidney injury at admission according to KDIGO classification
* Measurement of serum uric acid, albumin, and lactate levels at ICU admission
* SOFA score calculated at ICU admission
* ICU follow-up of at least 24 hours

Exclusion Criteria

* Age under 65 years
* Uncompensated or decompensated chronic liver disease (e.g., Child-Pugh class C)
* Chronic kidney disease stage 4 or 5 (eGFR \<30 mL/min/1.73 m²)
* Presence of acute kidney injury at admission according to KDIGO criteria
* Active malignancy or receipt of active cancer treatment within the last 6 months
* Missing or incomplete clinical/laboratory data
* ICU follow-up less than 24 hours

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No